{"nctId":"NCT00338286","briefTitle":"A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy","startDateStruct":{"date":"2006-03-02","type":"ACTUAL"},"conditions":["Breast Cancer","Neoplasm Metastasis"],"count":2098,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: epoetin alfa + packed RBC transfusion"]},{"label":"002","type":"OTHER","interventionNames":["Other: Standard supportive care (packed RBC transfusion)"]}],"interventions":[{"name":"Standard supportive care (packed RBC transfusion)","otherNames":[]},{"name":"epoetin alfa + packed RBC transfusion","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed (e.g., slide of tissue) breast cancer\n* HER2/NEU positive or negative\n* Clinical evidence of metastasis (e.g., biopsy) with at least 1 measurable metastatic (M1) lesion prior to starting the current chemotherapy\n* Received 1st and 2nd line chemotherapy\n* Hemoglobin (Hb) \\<= 11g/dL at the time of randomization\n* planned to receive at least 2 more cycles of chemotherapy\n* Life expectancy \\> 6 months\n* Eastern Cooperative Oncology Group score 0 or 1\n* At least 18 years old using effective birth control or surgically sterile or postmenopausal for 1 year\n\nExclusion Criteria:\n\n* Active second cancer\n* no recent history of clinically relevant thrombovascular event\n* Current treatment with anticoagulants\n* Brain metastasis or CNS involvement\n* Anemia secondary to another cause\n* Recent (within prior 1 months) use of an ESA\n* Patient pregnant or breast feeding\n* Progressive disease during adjuvant/neoadjuvant chemotherapy\n* Rapidly progressive or life-threatening metastatic disease\n* Concomitant endocrine therapy\n* Patient in whom the only site of metastasis was local and was successfully treated surgically.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"Progression free survival was based in investigator-determined progressive disease (PD) and calculated from the date of randomization to the date of PD or the date of death, whichever occurred first. Participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the clinical cutoff. For PD or death with a missing interval immediately preceding the event, progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval. Participants who withdrew from the study (withdrawal of consent or lost to follow-up) without progression were censored at the time of the last disease assessment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival (OS) was defined as the interval between the date of randomization to the date of death from any cause. For participants who were lost to follow-up or withdrew before the final database lock, OS was censored at the last date the participants was known to be alive. For participants who were still alive and on study at the time of the final database lock, OS was censored at the date of final database lock.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Tumor Progression","description":"The Time to tumor progression (TTP) was defined as the time from the date of starting treatment until the date of first documented evidence of progression of tumor. TTP was measured from the date of randomization to the date of the first documented PD (including death due to PD without prior PD).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR)","description":"Overall response was RECIST criteria. Complete response (CR) is appearance of all target and non-target lesions. Partial response (PR):a) 30% decrease in sum of lactate dehydrogenase(LD) of target lesions from baseline OR b) complete disappearance of target lesions, with persistence of one or more non-target measurable lesion or one or more non-measurable, evaluable lesions. Progressive disease(PD):a) 20% increase in sum of LDs of target lesions, taking as reference smallest sum LD recorded since treatment started; OR b) appearance of one or more new lesions or a clear worsening of measurable non-target lesions or evaluable disease with stable measurable lesions. Stable disease (SD):a) sufficient shrinkage to qualify for PR;b) sufficient increase to qualify for PD. Non evaluable(NE) lesion: all other lesions, including small lesions (longest diameter \\<20 millimeter (mm) with conventional techniques or \\<10 mm with spiral CT scan) and truly non-measurable lesions.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Suspected Thrombotic Vascular Events (TVEs)","description":"Suspected TVEs were identified by investigators and relevant clinical information was collected.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.72","spread":null},{"groupId":"OG001","value":"4.86","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":229,"n":1045},"commonTop":["Neutropenia","Alopecia","Leukopenia","Nausea","Fatigue"]}}}